このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

A Study of HB1801 Versus Docetaxel (Taxotere®) in Patients With Advanced Breast Cancer

A Randomized, Open-Label, Multicenter Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of HB1801 Versus Docetaxel (Taxotere®) in Patients With Advanced Breast Cancer

This is a randomized, open-label, multicenter Phase Ⅲ clinical trial designed to evaluate the efficacy and safety of HB1801 versus Taxotere® in patients with HER2-negative advanced breast cancer.

調査の概要

状態

まだ募集していません

研究の種類

介入

入学 (推定)

430

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Clinical Trials Information Group Officer
  • 電話番号:86-0311-69085587
  • メール:ctr-contact@cspc.cn

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  • 1. Age: 18-75 years (Whichever is on the day of signing the informed consent form).
  • 2. Subjects have histologically or cytologically confirmed breast cancer at unresectable,recurrent/metastatic stage, with the requirements below based on the most recent pathological report:

    1. HER2-negative confirmed by histological or cytological testing;
    2. Pathological report is available to confirm HR status.
  • 3. Assessed by the Investigator as suitable for single-agent docetaxel therapy.
  • 4. At least one extracranial measurable lesion at baseline according to RECIST 1.1 criteria.
  • 5. Has adequate organ and system functions within 7 days prior to the first dose.
  • 6. Eastern Cooperative Oncology Group performance status of 0 or 1.
  • 7. Expected survival ≥ 3 months.

Exclusion Criteria:

  • 1. Has received prior taxane-containing single-agent or combination regimens, and have disease progression during salvage therapy for unresectable locally advanced or metastatic breast cancer (has received at least 2 cycles), or developed recurrent-metastatic disease within 12 months following adjuvant therapy.
  • 2. History of severe allergy or hypersensitivity reactions (Grade ≥3 per NCI-CTCAE Version 6.0) to human serum albumin or docetaxel and/or contraindications thereto, or history of severe allergy and/or contraindications to glucocorticoids.
  • 3. Untreated active brain metastases (including brain or leptomeningeal metastases). Subjects with treated brain metastases may be enrolled if lesions are stable without evidence of new or enlarging pre-existing brain metastases.
  • 4. With a history of other primary malignant tumors within 5 years before administration.
  • 5. Presence of serous cavity effusion requiring drainage or diuretic therapy within 2 weeks prior to the first dose.
  • 6. Severe neurological diseases (e.g., epilepsy, dementia, etc.) and Grade ≥2 peripheral neuropathy.
  • 7. Receipt of systemic glucocorticoid therapy within 14 days prior to the first dose.
  • 8. Current clinically significant abnormal interstitial lung disease.
  • 9. History of severe cardiovascular and cerebrovascular diseases within 6 months prior to the first dose.
  • 10. Has arterial or venous thromboembolism (e.g., lower-extremity deep vein thrombosis, lower-extremity arterial embolism, pulmonary embolism, etc.) within 6 months prior to the first dose. Stable thrombus is permitted for enrollment if the Investigator assesses no associated cardiovascular risk.
  • 11. Severe chronic or active infection requiring intravenous antibacterial, antifungal, or antiviral therapy within 2 weeks prior to the first dose.
  • 12. Has undergone major visceral organ surgery (excluding puncture biopsy or infusion device implantation) within 4 weeks prior to the first dose, or who require major visceral organ surgery during the study period.
  • 13. Receipt of chemotherapy, targeted therapy, immunotherapy, endocrine therapy, or other investigational study drug within 4 weeks or 5 half-lives prior to the first dose (whichever is shorter, with a minimum of 2 weeks); receipt of radiotherapy within 2 weeks prior to the first dose; receipt of traditional Chinese medicine with anti-tumor indications within 2 weeks prior to the first dose.
  • 14. Toxicities from all prior anti-tumor therapies have not recovered to Grade 1 or less prior to the first dose.
  • 15. Has received powerful CYP3A4 inhibitor or inducer within 2 weeks before the first dose.
  • 16. Has active hepatitis B infection, hepatitis C infection, positive HIV antibody, or active syphilis.
  • 17. Concurrent participation in another interventional clinical study.
  • 18. Any other conditions that, in the Investigator's opinion, render the participant unsuitable for participation in this clinical trial.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:HB1801
HB1801, 100 mg/m² in Cycle 1, 75 mg/m² starting from Cycle 2, once every 3 weeks (Q3W), intravenous infusion over 60 minutes.
実験的:Docetaxel (Taxotere®)
Docetaxel (Taxotere®), 75 mg/m², Q3W, intravenous infusion over 60 minutes.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Progression-free Survival (PFS)
時間枠:up to approximately 2 years after the first enrollment
PFS was defined as the time from the date of randomization to the date of progressive disease (as per RECIST v1.1) or death due to any cause.
up to approximately 2 years after the first enrollment

二次結果の測定

結果測定
メジャーの説明
時間枠
Objective Response Rate (ORR) assessed per RECIST v1.1
時間枠:up to approximately 2 years after the first enrollment
ORR per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) assessed by investigator was defined as the percentage of participants with complete response (CR) or partial response (PR).
up to approximately 2 years after the first enrollment
Duration of Response (DOR)
時間枠:up to approximately 2 years after the first enrollment
DOR by investigator assessment according to RECIST 1.1 in participants with CR or PR, defined as the time from the first documented CR/PR to PD or death.
up to approximately 2 years after the first enrollment
Disease Control Rate (DCR)
時間枠:up to approximately 2 years after the first enrollment
DCR by investigator assessment according to RECIST 1.1, defined as the percentage of participants with CR, PR, or stable disease (SD) lasting at least 6 weeks.
up to approximately 2 years after the first enrollment
Overall Survival (OS)
時間枠:up to approximately 2 years after the first enrollment
OS was defined as the time from the date of randomization until death due to any cause regardless of whether the participant withdrew from study therapy or received another subsequent anticancer therapy.
up to approximately 2 years after the first enrollment
The incidence and severity of adverse events (AE) and severe adverse events (SAE)
時間枠:up to approximately 2 years after the first enrollment
up to approximately 2 years after the first enrollment
Plasma concentration of docetaxel (free and total)
時間枠:After completion of infusion administration on Day 1 of Cycle 1
After completion of infusion administration on Day 1 of Cycle 1

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年8月31日

一次修了 (推定)

2028年6月1日

研究の完了 (推定)

2029年6月1日

試験登録日

最初に提出

2026年8月28日

QC基準を満たした最初の提出物

2026年9月3日

最初の投稿 (実際)

2026年9月4日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月4日

QC基準を満たした最後の更新が送信されました

2026年9月3日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する